Quantitation of interference in digoxin immunoassay in renal, hepatic, and diabetic disease.
A comparison of the results of a newly developed fluorescence-derivatization/HPLC method and a commercial immunoassay method (ACA, Dupont) for the measurement of serum digoxin concentrations in patients indicates that (1) the results from the ACA method agree well with those from the HPLC method in patients with cardiovascular disease but without renal, diabetic, and liver disease, (2) serum digoxin concentrations determined by the ACA method are overestimated in patients with renal, diabetic, or liver disease, and (3) the steady-state serum concentrations of hydrolyzed and reduced metabolites are relatively insignificant in patients receiving digoxin therapy, including patients with renal failure. The excellent reproducibility of the HPLC and immunoassay methods (coefficient of variation < 9.0%), together with the demonstrated specificity of the HPLC method with respect to potential interference from digoxin metabolites, endogenous digoxin-like immunoactive substances, and coadministered drugs and their metabolites, allows quantitation of the degree of interference in digoxin immunoassays under actual therapeutic drug monitoring conditions. Clinically significant interferences (0.3 to 1.1 ng/ml) with immunoassay determination were found in the majority of patients in all three diseases studied.
Tzou
M C
MC
College of Pharmacy, Ohio State University, Columbus 43210, USA.
Reuning
R H
RH
Sams
R A
RA
D000328:Adult; D000368:Aged; D002316:Cardiotonic Agents / Q000097:blood*; D002851:Chromatography, High Pressure Liquid; D003920:Diabetes Mellitus / Q000097:blood* / Q000503:physiopathology; D004077:Digoxin / Q000097:blood*; D005260:Female; D005453:Fluorescence; D006801:Humans; D007118:Immunoassay; D007674:Kidney Diseases / Q000097:blood* / Q000503:physiopathology; D008107:Liver Diseases / Q000097:blood* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged
D002316:Cardiotonic Agents; D004077:Digoxin